Iparomlimab and tuvonralimab
Multispecific antibody
Also known as QL1706
Evidence outlook
Approved: Recurrent or refractory cervical carcinoma that progressed on or after platinum-based... (CN)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
Also in development:Metastatic Colorectal Cancer · Phase 3 · investigational in the US
Also approved (1)
- Recurrent or refractory cervical carcinoma that progressed on or after platinum-based chemotherapy (conditional approval; iparomlimab + tuvonralimab, trade name Qibei'an)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05690945 NCT05690945 · Lung Cancer Registry: NCT05690945 | 3 | OS (From date of randomization until the date of death from any cause, which ever came first, assessed up to 2 years) 2029-06 | In progress: results expected 1 Jun 2029 | not yet graded | link ↗ |
View 1 more trial
NCT05487391 NCT05487391 · Carcinoma, Non-Small-Cell Lung Registry: NCT05487391 | 3 | Disease-free Survival (DFS) in the PD-L1 ≥1% Population, Assessed by Investigator. (Up to approximately 84 months); Disease-free Survival (DFS) in the ITT Population, Assessed by Investigator. (Up to approximately 84 months) 2027-08-31 | In progress: results expected 31 Aug 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (146)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other PD-1 x CTLA-4 drugs
Volrustomig, Danvilostomig, Lorigerlimab, AI-061. Compare all 5 PD-1 x CTLA-4 drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Metastatic Colorectal Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Iparomlimab And Tuvonralimab: this drug | Phase 3 | Multispecific antibody | PD-1 x CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Capecitabine | ApprovedUS marketing discontinued | Small molecule | Fluoropyrimidine (antimetabolite) | not yet graded | No reviewed efficacy summary in this indication | |
| Cetuximab | Approved | Monoclonal antibody | EGFR | Partial signal | NCT00154102: Progression-free survival (IRC), cetuximab + FOLFIRI vs FOLFIRI: median 8.9 vs 8.0 months, hazard ratio 0.853 (95% CI 0.728 to 1.000), p=0.0479 (n=599 each). Later KRAS analyses: wild-type HR 0.696 (95% CI 0.558 to 0.867), p=0.0012; mutant HR 1.171 (95% CI 0.887 to 1.544), p=0.2648 (CT.gov posted results). | |
| Encorafenib | Approved | Small molecule | BRAF V600E | not yet graded | No reviewed efficacy summary in this indication | |
| Fruquintinib (Fruzaqla / Elunate) | Approved | Small molecule | VEGFR1/2/3 | Reliable signal | NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001 | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Weak signal | No reviewed efficacy summary in this indication | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Weak signal | NCT02460198: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48) | |
| Ramucirumab | Approved | Monoclonal antibody | VEGFR2 | Partial signal | NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7) | |
| Regorafenib | Approved | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | Reliable signal | NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016) | |
| Sotorasib | Approved | Small molecule | KRAS G12C | not yet graded | No reviewed efficacy summary in this indication | |
| Tucatinib | Approved | Small molecule | HER2 | Partial signal | NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5) | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Zirabev (bevacizumab-Bvzr) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ivonescimab | Phase 3 | Multispecific antibody | PD-1 + VEGFA | not yet graded | No reviewed efficacy summary in this indication | |
| Precemtabart Tocentecan | Phase 3 | Antibody–drug conjugate | CEACAM5 | not yet graded | No reviewed efficacy summary in this indication | |
| Eniluracil | Phase 2 | — | Dihydropyrimidine dehydrogenase (DPD) | not yet graded | No reviewed efficacy summary in this indication | |
| Leronlimab | Phase 2 | Monoclonal antibody | CCR5 co-receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Lorigerlimab | Phase 2(overall) | Multispecific antibody | PD-1 x CTLA-4 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| LYL273 | Phase 1/2(overall) | Cell therapy | GCC (guanylyl cyclase C, GUCY2C) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(157 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Iparomlimab and tuvonralimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.